Slide 1: Emergent Acquisition of PaxVax Conference Call Speakers
Emergent Acquisition of PaxVax Conference Call Speakers EMERGENT BIOSOLUTIONS Robert Burrows Vice President, Investor Relations Robert Kramer President and Chief Operating Officer Adam Havey Executive Vice President, Business Operations Richard Lindahl Executive Vice President and Chief Financial Of
Slide 2: Conference Call Agenda
Emergent Acquisition of PaxVax Conference Call Agenda Benefits of the Transaction Kramer PaxVax Overview Havey Financial and Other Considerations Lindahl Key Takeaways Kramer Q&A Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation co
Slide 3: Forward-Looking Statements / Non-GAAP Financial Measures / Trademarks
Emergent Acquisition of PaxVax Forward-Looking Statements / Non-GAAP Financial Measures / Trademarks At a Glance Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary mat
Slide 4: Benefits of the Transaction
Benefits of the Transaction Robert Kramer President and Chief Operating Officer
Slide 5: PaxVax Acquisition is Strategically, Operationally and Financially Attractive
Benefits of the Transaction PaxVax Acquisition is Strategically, Operationally and Financially Attractive STRATEGIC Solidifies leadership position in public health threats market with addition of two revenue-generating FDA-licensed vaccines – Vivotif® for typhoid and Vaxchora® for cholera – both wit
Slide 6: PaxVax Overview
PaxVax Overview Adam Havey Executive Vice President, Business Operations
Slide 7: PaxVax is a Specialty Vaccines Company
PaxVax Overview PaxVax is a Specialty Vaccines Company Focused on the Development and Commercialization of Travelers’ Vaccines Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual result
Slide 8: PaxVax's Product Portfolio Adds Marketed and Clinical-Stage Assets
PaxVax’s Product Portfolio Adds Marketed and Clinical-Stage Assets Focused on Travel Vaccines Market PaxVax Overview Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary
Slide 9: Overview of Typhoid Fever and Cholera
Overview of Typhoid Fever and Cholera PaxVax Overview Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary materially. Emergent disclaims any duty to update to reflect n
Slide 10: PaxVax's Product Portfolio Adds Two Marketed Products
PaxVax’s Product Portfolio Adds Two Marketed Products PaxVax Overview Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary materially. Emergent disclaims any duty to upd
Slide 11: Vivotif is a Proven and Established Typhoid Vaccine
Vivotif® is a Proven and Established Typhoid Vaccine PaxVax Overview Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary materially. Emergent disclaims any duty to upda
Slide 12: Vaxchora was Approved in the US in 2016
Vaxchora® was Approved in the US in 2016 PaxVax Overview Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary materially. Emergent disclaims any duty to update to reflec
Slide 13: Commercial Operations Adds New Sales, Marketing and Distribution Capabilities
Commercial Operations Adds New Sales, Marketing and Distribution Capabilities Focused on Infectious Diseases PaxVax Overview Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results
Slide 14: PaxVax's Portfolio Adds Two Key Clinical-Stage Candidates
PaxVax’s Product Portfolio Adds Two Key Clinical-Stage Candidates Focused on Infectious Diseases of High Interest to US Military PaxVax Overview Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements,
Slide 15: European-Based Manufacturing Site Broadens CDMO Capabilities
European-Based Manufacturing Site Broadens CDMO Capabilities and Establishes International Footprint PaxVax Overview Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary
Slide 16: Financial and Other Considerations
Financial and Other Considerations Richard Lindahl Executive Vice President and Chief Financial Officer
Slide 17: All-Cash Consideration Reflects Efficient Use of Balance Sheet
Financial and Other Considerations All-Cash Consideration Reflects Efficient Use of Balance Sheet TRANSACTION Purchase price of $270M all cash Cash-free and debt-free acquisition of 100% of PaxVax FINANCING Committed credit facility of $200M in place Existing cash balance of $190M (at 6/30/2018) Pro
Slide 18: Transaction Contributes to Growth in Emergent's Financial Performance
Financial and Other Considerations Transaction Contributes to Growth in Emergent’s Financial Performance Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary materially.
Slide 19: Transaction Expected to Close in Q4 2018
Financial and Other Considerations Transaction Expected to Close in Q4 2018 Approved by Boards of Directors of both companies Structured as a merger agreement Subject to customary closing conditions Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation.
Slide 20: Key Takeaways
Key Takeaways Robert Kramer President and Chief Operating Officer
Slide 21: Transaction Further Solidifies Emergent as a Leader in Public Health Threats Market
Key Takeaways Transaction Further Solidifies Emergent as a Leader in the Public Health Threats Market Provided August 9, 2018 as part of an oral presentation and is qualified by the entire presentation. This presentation contains forward-looking statements, and actual results may vary materially. Em
Slide 22: Q&A
Q&A Robert Kramer President and Chief Operating Officer Adam Havey Executive Vice President, Business Operations Richard Lindahl Executive Vice President and Chief Financial Officer Abigail Jenkins Senior Vice President and Vaccines & Anti-Infectives Business Unit Head Sean Kirk Senior Vice Presiden
Slide 23: Q&A
o— emergent Q&A Robert Kramer President and Chief Operating Officer Adam Havey Executive Vice President, Business Operations Richard Lindahl Executive Vice President and Chief Financial Officer Abigail Jenkins Senior Vice President and Vaccines & Anti-Infectives Business Unit Head Sean Kirk Senior V